Magnetic Seizure Therapy: Towards Personalized Seizure Therapy for Major Depression.

MST Magnetic seizure therapy depression neurocognition neuromodulation

Journal

Personalized medicine in psychiatry
ISSN: 2468-1725
Titre abrégé: Pers Med Psychiatry
Pays: United States
ID NLM: 101699535

Informations de publication

Date de publication:
Historique:
entrez: 25 8 2020
pubmed: 25 8 2020
medline: 25 8 2020
Statut: ppublish

Résumé

Magnetic seizure therapy (MST) is a noninvasive neuromodulation therapy under investigation for the treatment of severe neuropsychiatric disorders. MST involves inducing a therapeutic seizure under anesthesia in a setting similar to electroconvulsive therapy (ECT). To date, randomized controlled trials suggest that MST has similar antidepressant efficacy as ECT, but without significant cognitive adverse effects. Large scale clinical trials are currently underway to confirm these preliminary findings. So far, there has only been one study evaluating the clinical predictors of response to MST and more research is needed. This study found that patients with fewer episodes of depression and a positive family history of depression had a better response to MST. Overall, the ability of MST to focus the delivery of the electric field and the resultant seizure makes targeting seizure therapy to specific brain regions possible, and further research will be helpful in identifying personalized targets to maximize clinical benefit. In this review, we describe MST methodology and how it could be individualized to each patient. We also summarize the clinical and cognitive effects of MST and provide indications of which patients may be most likely to benefit. Finally, we summarize the studied neurophysiological predictors of response.

Identifiants

pubmed: 32832741
doi: 10.1016/j.pmip.2019.04.003
pmc: PMC7442165
mid: NIHMS1530603
doi:

Types de publication

Journal Article

Langues

eng

Pagination

37-42

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH112815
Pays : United States

Références

Transl Psychiatry. 2018 Nov 23;8(1):253
pubmed: 30470735
Neuropsychopharmacology. 2003 Nov;28(11):2045-8
pubmed: 12942146
Neuroimage. 2009 Sep;47(3):1086-91
pubmed: 19497373
Neuroimage Clin. 2018;20:1176-1190
pubmed: 30388600
Neuropsychopharmacology. 2015 Aug;40(9):2076-84
pubmed: 25920013
JAMA Psychiatry. 2016 Apr;73(4):337-45
pubmed: 26981889
J ECT. 2014 Jun;30(2):165-76
pubmed: 24820942
J ECT. 2015 Mar;31(1):13-9
pubmed: 24853650
Clin Neurophysiol. 2018 Aug;129(8):1770-1779
pubmed: 29735419
Brain. 2017 Apr 1;140(4):1011-1025
pubmed: 28335039
Br J Anaesth. 2014 Apr;112(4):695-702
pubmed: 24305645
Depress Anxiety. 2018 May;35(5):393-401
pubmed: 29329499
Front Psychiatry. 2018 May 29;9:224
pubmed: 29896130
J Psychiatr Res. 2011 May;45(5):569-76
pubmed: 20951997
Br J Psychiatry. 2008 Aug;193(2):152-5
pubmed: 18670002
Anesth Analg. 2006 Jul;103(1):76-80, table of contents
pubmed: 16790630
Psychiatry Clin Neurosci. 2007 Apr;61(2):168-73
pubmed: 17362434
J Clin Psychiatry. 2008 Mar;69(3):406-11
pubmed: 18278988
Conf Proc IEEE Eng Med Biol Soc. 2015 Aug;2015:2203-6
pubmed: 26736728
Neuropsychopharmacology. 2004 Apr;29(4):813-25
pubmed: 14735129
J ECT. 2016 Jun;32(2):88-92
pubmed: 26397151
J ECT. 2018 Jun;34(2):95-103
pubmed: 29240021
Front Psychiatry. 2018 Mar 21;9:92
pubmed: 29618992
Neuropsychiatr Dis Treat. 2014 Oct 31;10:2049-55
pubmed: 25382978
Neuropsychopharmacology. 2003 Oct;28(10):1852-65
pubmed: 12865903
Crit Rev Biomed Eng. 1999;27(3-5):241-84
pubmed: 10864281
Eur Neuropsychopharmacol. 2013 Nov;23(11):1541-50
pubmed: 23820052
J ECT. 2019 Jun;35(2):135-138
pubmed: 29979250
Int Rev Psychiatry. 2011 Oct;23(5):413-23
pubmed: 22200131
J Psychiatry Neurosci. 2017 Jan;42(1):6-16
pubmed: 27327561
Arch Gen Psychiatry. 2001 Mar;58(3):303-5
pubmed: 11231838
Front Psychiatry. 2018 Jan 16;8:310
pubmed: 29387022
Clin EEG Neurosci. 2008 Jul;39(3):144-9
pubmed: 18751564
J Neural Eng. 2011 Feb;8(1):016007
pubmed: 21248385
J ECT. 2019 Mar;35(1):48-52
pubmed: 29613946
Neurosci Lett. 2018 Mar 16;669:32-42
pubmed: 27793702
Psychiatry Res. 2013 Feb 28;211(2):169-75
pubmed: 23149039
Psychol Med. 2015 Apr;45(5):1073-92
pubmed: 25420474

Auteurs

Elisa Kallioniemi (E)

Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA.

Shawn M McClintock (SM)

Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA.
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.

Zhi-De Deng (ZD)

Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.
Noninvasive Neuromodulation Unit, Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.

Mustafa M Husain (MM)

Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA.
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.

Sarah H Lisanby (SH)

Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.
Noninvasive Neuromodulation Unit, Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.

Classifications MeSH